▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3119 by analyst upside · 2026-11-13
TEVA
Teva Pharmaceutical Industries Limited
Healthcare · Market Cap $51B · P/E 101.5x
ANALYST PRICE TARGET
+13.3%
implied upside to consensus target
Current Price $43.65
Consensus Target $49.44
Bull Target $57.0
Bear Target $42.12
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
8
Hold
2
Sell
0
52-Week Low $24.01
52-Week High $44.31
YTD Return +41.0%
FUNDAMENTALS
Market Cap $51B
P/E Ratio (TTM) 101.5x
Forward P/E 14.0x
EPS (TTM) $0.43
PEG Ratio 0.71
Dividend Yield N/A
Revenue (TTM) $17.2B
Profit Margin 2.9%
52-WEEK RANGE
52-Week Low $24.01
52-Week High $44.31
Current Price $43.65
Bear Target $42.12
Bull Target $57.0
● Now $43.65 ● Target $49.44
TRADING DATA
Avg Volume 6.0M
YTD Return +41.0%
Analyst Count 14
Consensus Buy
Upside to Target +13.3%
Last Updated 2026-11-13

ANALYST SUMMARY

Teva Pharmaceutical Industries Limited (TEVA) is currently trading at $43.65 with a Wall Street consensus price target of $49.44, implying potential upside of 13.3% over the next 12 months. 14 analysts currently cover TEVA, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $57.0, while the most cautious has a target of $42.12.

TEVA operates in the Healthcare sector with a market capitalisation of $51B. The stock is up 41.0% year-to-date and is currently trading near the upper end of its 52-week range of $24.01 – $44.31.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TEVA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners - Reiterated
Outperform → Outperform 2026-11-05 29% win rate (7 calls)
TD Cowen - Reiterated
Buy → Buy 2026-11-04 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-11-04 31% win rate (48 calls)
HC Wainwright & Co. ● Initiated
Buy 2026-11-02 31% win rate (48 calls)
Barclays - Reiterated
Overweight → Overweight 2026-10-15 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-10-12 43% win rate (7 calls)
TD Cowen ● Initiated
Buy 2026-10-01 Building track record
Oppenheimer ● Initiated
Outperform 2026-09-23 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
66
out of 100
Coverage depth
21/30
Consensus clarity
23/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →